2022 Project: University of California, San Francisco (UCSF)

Characterization of host and immune responses to different SARS-CoV-2 variants and association with disease severity
For Public Health

What to know

The team at UCSF plans to combine whole-genome sequencing for SARS-CoV-2 variants with host transcriptome and antibody analyses to develop models for predicting poor outcomes of SARS-CoV-2 infection and likelihood of vaccine breakthrough or re-infection.
Decorative image with words "2022" and "SARS-CoV-2"

Findings on SARS-CoV-2 surveillance and investigations

This project provided a systems-level view of immune responses and tissue damage in COVID-19 and MIS-C which could inform future development of new disease biomarkers.1

Awarded in 2022, this project is still in progress.

Print
Content Source
Error processing SSI file
About This Page
Published: May 15, 2024
Updated: January 29, 2024

This page was last updated on this date. Updates may include minor edits, image changes, or other modifications to page content.

Reviewed: January 29, 2024

The information on this page was last reviewed by subject matter experts to ensure accuracy.

  1. Nucleic acid biomarkers of immune response and cell and tissue damage in children with COVID-19 and MIS-C - PMC (nih.gov) Cell Rep Med